- Home
- PMEC vs ATNM Comparison
PMEC vs ATNM Comparison
Compare PMEC & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMEC
- ATNM
- Stock Information
- Founded
- PMEC 1984
- ATNM 2000
- Country
- PMEC Singapore
- ATNM United States
- Employees
- PMEC N/A
- ATNM N/A
- Industry
- PMEC
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- PMEC
- ATNM Health Care
- Exchange
- PMEC Nasdaq
- ATNM Nasdaq
- Market Cap
- PMEC 56.9M
- ATNM 50.2M
- IPO Year
- PMEC 2023
- ATNM N/A
- Fundamental
- Price
- PMEC $1.80
- ATNM $1.61
- Analyst Decision
- PMEC
- ATNM Strong Buy
- Analyst Count
- PMEC 0
- ATNM 2
- Target Price
- PMEC N/A
- ATNM $4.50
- AVG Volume (30 Days)
- PMEC 239.8K
- ATNM 122.2K
- Earning Date
- PMEC 01-01-0001
- ATNM 11-13-2025
- Dividend Yield
- PMEC N/A
- ATNM N/A
- EPS Growth
- PMEC N/A
- ATNM N/A
- EPS
- PMEC N/A
- ATNM N/A
- Revenue
- PMEC $74,349,000.00
- ATNM N/A
- Revenue This Year
- PMEC N/A
- ATNM N/A
- Revenue Next Year
- PMEC N/A
- ATNM N/A
- P/E Ratio
- PMEC N/A
- ATNM N/A
- Revenue Growth
- PMEC 2.52
- ATNM N/A
- 52 Week Low
- PMEC $0.54
- ATNM $1.03
- 52 Week High
- PMEC $1.89
- ATNM $2.41
- Technical
- Relative Strength Index (RSI)
- PMEC 56.41
- ATNM 45.72
- Support Level
- PMEC $1.76
- ATNM $1.60
- Resistance Level
- PMEC $1.88
- ATNM $1.70
- Average True Range (ATR)
- PMEC 0.10
- ATNM 0.07
- MACD
- PMEC 0.00
- ATNM -0.01
- Stochastic Oscillator
- PMEC 76.92
- ATNM 32.14
About PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.